









Markets
/
Stocks
/
nasdaq-ilmn
/

Illumina Inc

ILMN

100.920USD

+5.800+6.10%

Close 09/15, 16:00（ET）Quotes delayed by 15 min

15.54BMarket Cap

12.35P/E TTM



Illumina Inc

100.920

+5.800+6.10%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-15

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

61 / 207

Overall Ranking

195 / 4724

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 24 analysts

Hold

Current Rating

112.300

Target Price

+18.06%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

Overvalued

The company’s latest PE is 12.74, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 167.87M shares, decreasing 9.74% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 15.08M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.31.

Financial Health

Currency: USD Updated：2025-09-15

The company's current financial score is 8.01, which is higher than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 1.04B, representing a year-over-year decrease of 3.25%, while its net profit experienced a year-over-year decrease of 203.97%.

Score

Industry at a Glance

Previous score

8.01

Change

-0.35



Financials

8.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.23

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.02

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.29

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-15

The company’s current valuation score is 1.80, which is lower than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is 12.57, which is -2.29% below the recent high of 12.28 and 205.21% above the recent low of -13.22.

Score

Industry at a Glance

Previous score

1.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 61/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-15

The company’s current earnings forecast score is 6.92, which is lower than the Healthcare Equipment & Supplies industry's average of 7.66. The average price target for Illumina Inc is 110.00, with a high of 185.00 and a low of 75.00.

Score

Industry at a Glance

Previous score

6.92

Change

Support & Resistance

No Data

Analyst Rating

Based on 24 analysts

Hold

Current Rating

112.300

Target Price

+18.06%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Illumina Inc

ILMN

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-15

The company’s current price momentum score is 6.85, which is lower than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 107.38 and the support level at 91.94, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.55

Change

1.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.080

Sell

RSI(14)

54.312

Neutral

STOCH(KDJ)(9,3,3)

68.425

Buy

ATR(14)

3.127

High Vlolatility

CCI(14)

64.782

Neutral

Williams %R

1.274

Overbought

TRIX(12,20)

-0.084

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

97.812

Buy

MA10

97.774

Buy

MA20

98.941

Buy

MA50

99.477

Buy

MA100

91.873

Buy

MA200

101.586

Sell

Institutional Confidence

Currency: USD Updated：2025-09-15

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 109.04%, representing a quarter-over-quarter increase of 1.07%. The largest institutional shareholder is The Vanguard, holding a total of 15.08M shares, representing 9.81% of shares outstanding, with 1.19% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Capital World Investors

18.90M

+4.85%

The Vanguard Group, Inc.

Star Investors

16.30M

+3.51%

BlackRock Institutional Trust Company, N.A.

14.01M

-0.10%

State Street Global Advisors (US)

5.85M

+1.01%

WCM Investment Management

4.18M

+1.19%

Loomis, Sayles & Company, L.P.

4.15M

-1.50%

Corvex Management LP

3.83M

+125.25%

AQR Capital Management, LLC

2.12M

+361.72%

PointState Capital LP

2.52M

+56.19%

Risk Assessment

Currency: USD Updated：2025-09-15

The company's beta value is 1.44. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.